

Kateřina Rohlenov

Kateřina Rohlenov is a junior group leader at the Institute of Biotechnology, CAS in BIOCEV. After her PhD at the same institute, where she characterized a novel anti-cancer drug that later underwent a phase I clinical trial, she moved to VIB in Leuven, Belgium to study metabolism of endothelial cells. In 2020 she returned to the Czech Republic to establish a Cellular Metabolism group. With a team of 15 researchers (9 nationalities) her central focus is on the intercellular metabolic communication in tumors. Her research is funded by an ERC Starting grant and EMBO Installation grant, among others, and she has been awarded with prizes such as Werner Risau prize and Neuron prize for promising researchers.

